The treatment with pioglitazone in CAD patients with T2DM or metabolic syndrome, was shown to increase PPARγ in SAT and to selectively reduce the expression of IL-1β, IL-1Ra and IL-10 in EAT, and of IL-10 in SAT, irrespective of other clinical variables (weight, BMI, waist, fasting blood glucose, A1C, HOMA-IR, ACE inhibitors, angiotensin receptor blockers, statins, aspirin, and metformin) [120]. Here, IL1B is linked to type 2 diabetes mellitus.